Abstract
Annually, a subset of chronic patients is capable of controlling hepatitis B virus (HBV) replication long-term, similar to what is observed following acute resolving HBV infection. A more detailed understanding of the immune responses associated with HBV resolution could pave the way for new immunotherapeutic interventions. We have studied HBV-specific T cell immunity in chronic HBV-infected patients, as well as in acute and chronic patients with long-term HBV control, as the natural model for protective immunity. We have characterized HBV-specific T cell responses, using: multicolor flowcytometry, HLA-class I and II multimers, intracellular cytokine staining and IFN-y ELISpot assays.
Original language | English |
---|---|
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 24 Feb 2022 |
Place of Publication | Rotterdam |
Print ISBNs | 978-94-6458-026-6 |
Publication status | Published - 24 Feb 2022 |